R&D | December 08, 2025
Groundbreaking study identifies 250 genes driving ME & long COVID
76 of 180 long COVID-associated genes also linked to ME
76 of 180 long COVID-associated genes also linked to ME
StarGuide GX delivers ultra-high sensitivity and high-resolution imaging, enabling fast, confident diagnostics
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Viatel bioresorbable polymers are increasingly used in dental and orthopedic implants
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Subscribe To Our Newsletter & Stay Updated
